COSCIENS Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
COSCIENS Biopharma has a total shareholder equity of $26.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $50.0M and $23.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$27.80m |
Equity | US$26.23m |
Total liabilities | US$23.82m |
Total assets | US$50.05m |
Recent financial health updates
Recent updates
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk
Aug 29Aeterna slips ~10% after announcing date of reverse stock split
Jul 19Aeterna Zentaris names Michael Teifel as chief scientific officer
May 03Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%
Feb 02Financial Position Analysis
Short Term Liabilities: CSCI's short term assets ($33.2M) exceed its short term liabilities ($9.9M).
Long Term Liabilities: CSCI's short term assets ($33.2M) exceed its long term liabilities ($13.9M).
Debt to Equity History and Analysis
Debt Level: CSCI is debt free.
Reducing Debt: CSCI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CSCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CSCI has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 25.9% each year.